Lupin appoints Maurice Chagnaud to head European operations

He will also be responsible for developing company's core strategy for Inhalation in the developed markets

Lupin

Pharma major Lupin today appointed ex-Teva executive Maurice Chagnaud as its President, Europe and Head of Inhalation Strategy.

"In his new role at Lupin, Chagnaud will assume full responsibility for the Company's European business, including the company strategy for generics and specialty business in Western and CEE region, including Russia & CIS countries," the company said in a statement.

He will also be responsible for developing Lupin's core strategy for Inhalation in the developed markets.

Commenting on the appointment, Lupin Ltd Chief Executive Officer Vinita Gupta, said: "Over the years, Lupin has recorded consistent growth across advanced markets like the US and Japan. With Maurice's rich experience we look forward to building our business in Europe, in particular around complex generics and specialty."

He will be based at Schaffhausen, Switzerland.

Chagnaud has over 20 years of experience in Pharmaceutical business in Europe having worked with Teva and Merck Generics.

He joins Lupin from Israeli drug major, Teva, where he was the Senior Vice-President, Central and Eastern Europe (CEE).